• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

STUDY OF CLINICAL OUTCOME IN PATIENTS WITH DENGUE SYNDROME AT A TERTIARY HOSPITAL

    Sidaraya Hanjagi, Basavaraj P G

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 1666-1673

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Dengue fever is an acute febrile illness, approximately 0.3-14.9% develops severe manifestations that result in ICU admission, and 1-5% dies without early recognition and proper treatment. Present study was aimed to study clinical outcome in patients with dengue syndrome at a tertiary hospital.
Material and Methods: In present study was hospital based, observational study, conducted patients > 18 years age, had acute fever of < 10 days duration, had positive dengue serology (IgM antibodies/ NS-1) after at least 5 days of onset of fever. Treatment details were noted & final outcomes were analysed.
Results: In present study, 130 patients satisfying study criteria were included. Majority patients were from 31-40 years (29.23 %) followed by 41-50 years (24.62 %) & 19-30 years (21.54 %). Male patients (63.85 %) outnumbered female patients (36.15 %). Majority of patients had DF with warning sign (59.23 %), Dengue without warning sign (26.15 %) & Severe Dengue fever (DHF) (14.62 %). 23.85 % patients required hospitalization for > 6 days. Common clinical features in present study were fever (96.92 %), headache (83.85 %), myalgia (63.85 %), body pain (53.85 %), vomiting (43.08 %) & joint pain (33.08 %). As per dengue serology majority were NS 1 positive (75.38 %) as compared to NS1 positive + antibody (IgM) (24.62 %). In cases of severe Dengue fever (DHF)  (n= 19) crystalloids (100 %), colloids (78.95 %), PRBC (57.89 %), platelets (73.68 %) & FFP (31.58 %). Most of patients discharged uneventfully (68.42 %) while 5 deaths (26.32 %) were noted. Overall mortality in present study was 5.38 %.
Conclusion: Severe dengue disease, platelet count less than 50000, systemic involvement were common findings among patients died during course of treatment.
Keywords:
    Severe dengue disease platelet count < 50000 systemic involvement serological diagnosis
  • PDF (249 K)
  • XML
(2022). STUDY OF CLINICAL OUTCOME IN PATIENTS WITH DENGUE SYNDROME AT A TERTIARY HOSPITAL. European Journal of Molecular & Clinical Medicine, 9(1), 1666-1673.
Sidaraya Hanjagi, Basavaraj P G. "STUDY OF CLINICAL OUTCOME IN PATIENTS WITH DENGUE SYNDROME AT A TERTIARY HOSPITAL". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 1666-1673.
(2022). 'STUDY OF CLINICAL OUTCOME IN PATIENTS WITH DENGUE SYNDROME AT A TERTIARY HOSPITAL', European Journal of Molecular & Clinical Medicine, 9(1), pp. 1666-1673.
STUDY OF CLINICAL OUTCOME IN PATIENTS WITH DENGUE SYNDROME AT A TERTIARY HOSPITAL. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 1666-1673.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 42
  • PDF Download: 45
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus